Menlo Therapeutics Inc. (MNLO) financial statements (2021 and earlier)

Company profile

Business Address 520 U.S. HIGHWAY 22, SUITE 204
BRIDGEWATER, NJ 08807
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:597713660
Cash and cash equivalents58315010
Short-term investments1468749
Other undisclosed cash, cash equivalents, and short-term investments1   
Restricted cash and investments1   
Receivables16  1
Inventory, net of allowances, customer advances and progress billings7   
Inventory7   
Other undisclosed current assets4134
Total current assets:877814064
Noncurrent Assets
Operating lease, right-of-use asset21
Property, plant and equipment1000
Long-term investments and receivables   3
Long-term investments   3
Other noncurrent assets4   
Other undisclosed noncurrent assets 00 
Total noncurrent assets:6103
TOTAL ASSETS:947914067
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2110106
Accounts payable5432
Accrued liabilities11664
Employee-related liabilities4   
Debt1   
Deferred revenue and credits2
Other liabilities0   
Other undisclosed current liabilities 1  
Total current liabilities:2111108
Noncurrent Liabilities
Long-term debt and lease obligation34   
Long-term debt, excluding current maturities33   
Operating lease, liability1 
Liabilities, other than long-term debt  07
Deferred revenue and credits7
Other liabilities  00
Other undisclosed noncurrent liabilities1   
Total noncurrent liabilities:35 07
Total liabilities:56111015
Stockholders' equity
Stockholders' equity attributable to parent3769130(57)
Common stock0000
Additional paid in capital6042532412
Accumulated other comprehensive income (loss) 0(0)(0)
Accumulated deficit(566)(184)(111)(59)
Other undisclosed stockholders' equity   109
Total stockholders' equity:376913052
TOTAL LIABILITIES AND EQUITY:947914067

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues21 115
Revenue, net5
Cost of revenue(85)   
Gross profit:(64) 115
Operating expenses(187)(76)(65)(34)
Other undisclosed operating loss(1)   
Operating loss:(253)(76)(55)(30)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(1)33 
Interest and debt expense(4)   
Loss from continuing operations before equity method investments, income taxes:(258)(74)(51)(30)
Other undisclosed income from continuing operations before income taxes2   
Loss from continuing operations before income taxes:(256)(74)(51)(30)
Income tax benefit0   
Net loss:(256)(74)(51)(30)
Other undisclosed net income attributable to parent   1
Net loss available to common stockholders, diluted:(256)(74)(51)(29)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(256)(74)(51)(30)
Comprehensive loss:(256)(74)(51)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)0
Comprehensive loss, net of tax, attributable to parent:(256)(74)(51)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: